Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutations.

[1]  M. Caligiuri,et al.  FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2010, Blood.

[2]  Guido Marcucci,et al.  Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2010, Blood.

[3]  M. Caligiuri,et al.  Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[5]  R. Stuart,et al.  Quantifying the reduction in immunoglobulin use over time in patients with chronic immune thrombocytopenic purpura receiving romiplostim (AMG 531) , 2009, American journal of hematology.

[6]  S. Meshinchi,et al.  Structural and Functional Alterations of FLT3 in Acute Myeloid Leukemia , 2009, Clinical Cancer Research.

[7]  R. Latagliata,et al.  Negative impact of FLT3 abnormalities in elderly acute myeloid leukemia patients , 2008, Leukemia & lymphoma.

[8]  S. Fröhling,et al.  Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. , 2006, Blood.

[9]  Wolfgang Hiddemann,et al.  FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L). , 2005, Blood.

[10]  E. Estey,et al.  FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype. , 2004, Leukemia research.

[11]  B. Johansson,et al.  Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients , 2004, European journal of haematology.

[12]  S. Armstrong,et al.  FLT3 mutations in childhood acute lymphoblastic leukemia. , 2004, Blood.

[13]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Scott E. Smith,et al.  Acute myeloid leukemia in the older patient. , 2003, Critical reviews in oncology/hematology.

[15]  Axel Benner,et al.  Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. , 2002, Blood.

[16]  C. Bloomfield,et al.  Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.

[17]  J. Radich,et al.  FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. , 2001, Blood.

[18]  P. Bolufer,et al.  Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. , 2003, Haematologica.

[19]  P. Bolufer,et al.  Incidence and prognostic value of FLT 3 internal tandem duplication and D 835 mutations in acute myeloid leukemia , 2002 .

[20]  J. Radich,et al.  FLT 3 , RAS , and TP 53 mutations in elderly patients with acute myeloid leukemia , 2001 .

[21]  G. Ehninger,et al.  Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. , 2002, Blood.